Earnings call transcript: Bioventus Q3 2026 revenue miss sparks sharp selloff

Bioventus reported a Q3 2026 adjusted earnings of $0.17 a share, exceeding Wall Street's forecast of $0.16, but revenue of $142.4 million lagged behind the $149.51 million consensus. The mixed disclosure prompted a sharp 18.78% drop in shares to $10.681 in after-hours trading from the regular session's $13.15 close. Management also revised full-year revenue guidance to $590 million to $595 million, down from the prior midpoint of about $12 million higher.

While adjusted EPS was 6.25% higher than expected, revenue fell short by $7.11 million or 4.76%. The earnings beat was modest, but the revenue shortfall was more significant, as investors often prioritize sales momentum when assessing growth.